Patents Assigned to Genexine Inc.
-
Publication number: 20250026804Abstract: A high-concentration formulation of hGH fusion protein containing poloxamer 188 and polysorbate 80 and uses thereof are disclosed. The formulation containing poloxamer 188 and polysorbate 80 contains a high-concentration of hGH fusion protein has significantly reduced aggregation reactions and improved storage stability. The formulation can be a liquid formulation. The hGH fusion protein includes hGH and an immunoglobulin Fc polypeptide.Type: ApplicationFiled: October 19, 2022Publication date: January 23, 2025Applicants: Genexine, Inc., HANDOK INC.Inventors: Chanwoong PARK, Ki-Yong KIM
-
Publication number: 20230279069Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v%; and (d) a surfactant with a concentration of 0.05 to 6 w/v%. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.Type: ApplicationFiled: November 8, 2022Publication date: September 7, 2023Applicant: Genexine, Inc.Inventors: Donghoon CHOI, Changyong Eun, Seong Hoon Jeong, Jun Yeul LIM
-
Publication number: 20230123454Abstract: The present invention relates to a fusion protein including PD-L1 protein and a modified immunoglobulin Fc region and use thereof, and since the fusion protein has significantly higher purity and production yield compared to the existing fusion protein, has a high binding affinity to PD-1, reduces the proliferation of activated T cells, inhibits the generation of cytokines generated by activated T cells, and has an effect of inhibiting the infiltration of T cells or macrophages into tissues, it can be effectively used in the treatment of immune diseases.Type: ApplicationFiled: January 6, 2021Publication date: April 20, 2023Applicant: Genexine, Inc.Inventors: Young Chul SUNG, Eun Ju SHIN, Yuri HWANG, Sung Hee LEE
-
Patent number: 11357827Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.Type: GrantFiled: November 30, 2016Date of Patent: June 14, 2022Assignee: Genexine, Inc.Inventors: Moon Cheol Kang, Young Woo Choi, Donghoon Choi, Young Chul Sung
-
Publication number: 20220008515Abstract: The present disclosure relates to methods of treating a cancer (or a tumor) with an IL-7 protein in combination with an immune checkpoint inhibitor, such as a PD-1 antagonist (e.g., anti-PD-1 antibody) or a CTLA-4 antagonist (e.g., anti-CTLA-4 antibody).Type: ApplicationFiled: November 15, 2019Publication date: January 13, 2022Applicants: NeoImmuneTech, Inc., Genexine, Inc.Inventors: Seung-Woo LEE, Ji-Hae KIM, Saet-byeol JO, Han Wook PARK, Donghoon CHOI, Byung Ha LEE, Young Chul SUNG, Se Hwan YANG
-
Publication number: 20170158746Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.Type: ApplicationFiled: June 10, 2016Publication date: June 8, 2017Applicant: Genexine, Inc.Inventors: Se Hwan YANG, Donghoon CHOI, Hye Seong LIM
-
Patent number: 9000139Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.Type: GrantFiled: August 13, 2010Date of Patent: April 7, 2015Assignee: Genexine, Inc.Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
-
Patent number: 8883134Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.Type: GrantFiled: October 19, 2011Date of Patent: November 11, 2014Assignees: Handok Pharmaceuticals, Inc., Genexine, Inc.Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang
-
Patent number: 8586038Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: November 19, 2010Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)Inventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8586048Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry FoundationInventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8586531Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)Inventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8529899Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: September 10, 2013Assignees: Genexine, Inc., Postech Academy-Industry FoundationInventors: Sehwan Yang, Young Chul Sung
-
Patent number: 7989425Abstract: The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA and recombinant adenovirus, more particularly to a vaccine consisting of ? core-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, and method for administration of the vaccine by priming with the DNA vaccines described above and boosting with the recombinant adenovirus vaccine thereby enhancing the protective immunity to Hepatitis C virus.Type: GrantFiled: September 24, 2003Date of Patent: August 2, 2011Assignees: Genexine Inc., Postech Foundation, Dong-A Pharm. Co., Ltd., Daewood Co., Ltd., PoscoInventors: Young Chul Sung, Jin-Won Youn, Se-Hwan Yang, Su-Hyung Park, Chang Geun Lee
-
Publication number: 20050287117Abstract: The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA and recombinant adenovirus, more particularly to a vaccine consisting of ?core-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, and method for administration of the vaccine by priming with the DNA vaccines described above and boosting with the recombinant adenovirus vaccine thereby enhancing the protective immunity to Hepatitis C virus.Type: ApplicationFiled: September 24, 2003Publication date: December 29, 2005Applicants: Genexine Inc., Postech Foundation, Dong-A Pharm. Co., Ltd., Daewood Co., Ltd, PoscoInventors: Young Sung, Young Sung, Jin-won Youn, Se-Hwan Yang, Su-Hyung Park, Chang Lee